AstraZeneca Pharma India Limited — Important, 02-09-2025: Disclosure of material issue

**AstraZeneca Pharma India (AZPIL) Update:**

**Issue:** AZPIL has surrendered its manufacturing license, which was valid until December 2027, to authorities for cancellation. This move formalizes its complete exit from in-house production.

**Possible Impact:** This strategic shift, following an earlier announcement to exit its manufacturing site, means AZPIL will no longer directly produce its own medicines in India. Investors should consider the potential implications for its supply chain, as the company will likely rely on contract manufacturing or an import-based model going forward.

**Company's Action:** The surrender of the manufacturing license is the company's decisive step to finalize its planned exit from direct manufacturing operations.